{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.1","upperLimit":"96.6","value":"92.2"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"12.5","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the SPD of index lymph nodes.","dispersionType":"95% Confidence Interval","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG000","title":"Idelalisib + Rituximab"},{"description":"Placebo to match idelalisib administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG001","title":"Placebo + Rituximab"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set: randomized participants with treatment group designated according to initial randomization","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Lymph Node Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}